Curis regains Nasdaq bid price compliance, under one-year Panel Monitor
Curis received written notice from Nasdaq on July 24, 2026 that it has regained compliance with the bid price rule and is in full compliance with the Nasdaq Hearings Panel's terms. The company will be subject to a one-year Discretionary Panel Monitor from July 24, 2026, meaning any new continued listing deficiency would lead to a delist determination and a hearing without additional time to cure, and there is no assurance it will remain listed.
Key points
- Nasdaq notice dated July 24, 2026 confirms regained compliance with Listing Rule 5550(a)(2), the bid price rule
- Discretionary Panel Monitor applies for one year from July 24, 2026 under Listing Rule 5815(d)(4)(A)
- Any new continued listing deficiency during the monitor period gets no plan of compliance or extra time to cure
- Filing states there can be no assurance Curis will remain listed on Nasdaq
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.